Key points from article :
Announced that they have discontinued negotiations for a merger agreement.
Directors determined that it was in the best interest of their respective shareholders not to proceed.
Cited the diversity of the companies’ technology platforms and product development focus.
AgeX Therapeutics will continue to consider new strategic opportunities as they arise - including licensing agreements for UniverCyte and PureStem.
LyGenesis will continue its allogeneic cell therapy for patients with end stage liver disease, and preclinical cell organ regeneration therapies.